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Abstract 
Primary dysmenorrhoea is a common gynaecological complaint experienced by many females in 
their reproductive years. The aim of this systematic review was to synthesise the current 
evidence relating to the treatment of primary dysmenorrhoea with medicinal plants. Randomised 
clinical trials (RCTs) published in English between 2008 and 2016, pertaining to the use of 
medicinal plants for the treatment of primary dysmenorrhoea were assessed. Twenty-two RCTs 
were included in the review. Most medicinal plants, with the exception ofNoni (Morinda 
citrifolia),produced positive findings, with cinnamon (Cinnamomum zeylanicum), damask rose 
(Rosa damascena), dill (Anethumgraveolens), felty germander (Teucriumpolium), fennel 
(Foeniculum vulgare), fenugreek (Trigonellafoenum-graecum), lemon balm (Melissa officinalis), 
peppermint (Mentha piperita), rhubarb (Rheum emodi), and thyme (Thymus vulgaris) showing 
similar efficacy to commonly used NSAIDs (ibuprofen and mefanamic acid), while ginger 
(Zingiber officinale), valerian (Valeriana officinalis), wheat germ (Triticum aestivum) and 
yarrow (Achillea millefolium) showed efficacy in placebo-controlled trials. While further 
research is needed before definitive conclusions can be made, given their potential positive 
benefits and relative safety, these herbs may be considered on an individual basis.  
 
Keywords: medicinal plants, herbal medicines, phytotherapy, primary dysmenorrhoea, 
menstrual pain 
 
1. Introduction 
1.1 Problem Statement 
Primary dysmenorrhoea is a common gynaecological complaint, affecting up to 81% of 
menstruating females in their reproductive years (Juet al., 2014a), and has a negative impact on 
their quality of life. Conventional treatments include analgesics, the oral contraceptive pill 
(OCP) and/or non-steroidal anti-inflammatory drugs (NSAID’s), however these medications 
have been shown to have numerous side effects (Porter, 2011; Smith &Kaunitz, 2014). Herbal 
medicine is the study and/or practice of using medicinal plants for their therapeutic benefits, to 
counter and alleviate disease (Cooper et al., 2013). Medicinal plants are widely used globallyand 
there is a growing body of evidence relating to their efficacy in the treatment of a variety of 
conditions (Ekor, 2013). There is a need to continually evaluate and summarisethis research, 
which is beneficial to both allopathic and complementary medicine practitioners, as well as their 
patients.  
 
1.2 Aim 
 
 
The aim of this systematic review was to determine, evaluate and integrate evidence on the 
effectiveness of medicinal plants in the treatment of primary dysmenorrhoea. 
1.3 Definition of key concepts 
The concepts that are central to this study are defined as follows: 
Primary dysmenorrhoeais defined as cyclic pain of uterine origin, without pelvic pathology 
(Kuralet al., 2015).  
Medicinal plants includes the use of herbs, herbal materials, preparations, and products that 
contain as active ingredients parts of plants, or other plant materials, or combinations thereof, to 
prevent or treat disease (WHO, 2016). 
 
2. Methods 
This systematic review was conducted in accordance with PRISMA (Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses) and Cochrane Collaboration guidelines (Moher et 
al., 2009; Higgins & Green, 2008). The Allied and Complementary Medicine, Pubmed, Science 
Direct, Scopus, Springer Link andUjoogle databases were searched for relevant studies. RCTs 
involving the treatment of primary dysmenorrhoea using single medicinal plant applications 
compared to placebo or standard pharmaceutical treatment, published between 2008 and 2016 in 
English, were eligible for review. Only studies that assessed dysmenorrhoeal pain and associated 
symptoms as a primary or secondary outcome were considered eligible. Search terms and 
keywords used included: dysmenorrhoea, menstrual irregularities, uterine contractility, 
prostaglandin inhibitory effect, herbal medicine, medicinal plants, herbalism, and phytotherapy. 
Literature was evaluated for relevance by means of the title and abstract. Potentially eligible 
articles were read and assessed by two reviewers independently. Discrepancies were discussed 
with a third reviewer when necessary. The Jadad scoring system, a widely used and validated 
tool(Jadadet al., 1996; Berger &Alperson, 2010; Olivoet al., 2008) was used to evaluate the 
quality of the studies. Data from each study was recorded on the JBI data extraction form (The 
Joanna Briggs Institute, 2014), and included: author, year, study design and methodology, aim 
and outcome. Each study was further summarized. The risk of bias was assessed as low (+), 
unclear (?) or high (-) in seven domains, using the Cochrane Collaboration’s risk of bias 
tool(Cochrane Collaboration, 2016), which has become the standard approach to assess risk of 
bias in RCTs (Jørgensenet al., 2016).Permission to conduct this study was granted by the Faculty 
of Health Sciences Higher Degrees and Research Ethics Committees at the University of 
Johannesburg (Clearance numbers: HDC-01-09-2016/REC-01-11-2016). 
 
 
 
 
 
3. Theory 
3.1 Primary dysmenorrhoea 
Dysmenorrhoea is a common condition, and its prevalence rates vary from 45-90% worldwide 
(Poturet al., 2014). Only a small percentage of affected women consult a physician about their 
condition, and many choose to self-medicate (Potur&Komurcu, 2014; Ortiz, 2010). 
Dysmenorrhoea usually begins six to twelve months after menarche, once ovulation becomes 
regular (Kannan et al., 2015), and is typically described as a cramping pain in the lower 
abdomen during mentruation. Other associated symptoms may include: urinary frequency, 
diarrhoea, constipation, headache, vomiting and/or nausea (Edwards, 2008). Risk factors linked 
to prevalence include:females of a younger age and early menarche; nulliparity; irregular and 
profuse menstrual flow; a family history of dysmenorrhoea; and obesity. Psychological stress 
and lifestyle factors such as cigarette smoking, and poor dietalso increases the risk of developing 
dysmenorrhoea (Juet al., 2014b; Lattheet al., 2011; Parveenet al., 2009; Poturet al., 2014; 
Ozerdoganet al., 2009). 
 
3.2 Pathophysiology of Primary Dysmenorrhoea  
The pathophysiology of dysmenorrhoea has been linked to raised levels of prostaglandins within 
the endometrial fluid, which causes increased uterine contractions and peripheral nerve 
hypersensitivity, as well as ischaemia of the myometrium, resulting in menstrual pain (Singh & 
Rai, 2017). Prostaglandins are synthesized from prostanoids (biologically active derivatives of 
arachidonic acid), through the activity of cyclooxygenase-1 and cyclooxygenase-2 (COX 1 & 2) 
enzymes, which act as catalysts in the production of pro-inflammatory mediators (Dwivediet al., 
2015). High levels of circulating vasopressin and leukotrienes, which increase myometrial 
activity, may further precipitate this condition (Kolhe& Deb, 2011).  
 
3.3 Conventional treatment for Primary Dysmenorrhoea  
NSAIDs, including ibuprofen and mefenamic acid, are commonly used to alleviate menstrual 
pain as they inhibit prostaglandinproduction. The risk of developing adverse effects (such as 
headaches, drowsiness and gastrointestinal symptoms) from NSAID use is high, however is 
usually dosage dependant(Marjoribankset al., 2015).OCPs suppress ovulation, reduce 
endometrial tissue growth and consequentially result in less menstrual bleeding and 
prostaglandin synthesis. OCPs are also associated with numerous adverse effects, including: 
headaches, breast tenderness, weight gain, and mood swings, and increase the risk for developing 
 
 
venous thromboembolism and myocardial infarction and stroke (Dragoman, 2014; Singh & Rai, 
2017).  
 
3.4 Medicinal plants in the treatment of Primary Dysmenorrhoea  
The use of herbal medicines as an alternative treatment for dysmenorrhoea is a growing interest 
amongst many women (Mirabiet al., 2014). Herbal medicines excite physiological effects on the 
body to bring relief of symptoms and certain herbs have an anti-spasmodic, prostaglandin 
inhibiting and anti-inflammatory action; these may be a suitable alternative to conventional 
medicines for treating dysmenorrhoea, particularly in cases where these medicines are 
contraindicated or not well tolerated (Anuradha, 2015; Mirabiet al., 2014; Omidvaret al., 2012). 
 
4. Results and findings 
A total of 12 849 studies were retrieved from 6 databases. Of these, 405 studies were initially 
identified as potentially eligible, and a further 9 studies were retrieved by hand-searching of 
citations and references. Duplicates were removed and an overall of 279 studies remained. Of 
these, 252 studies were excluded after screening the title and abstract and 27 full text articles 
were included and assessed for eligibility; a further 5 articles were excluded for not meeting the 
inclusion criteria (Figure 1). The Jadad score and risk of bias assessment of the included RCTsis 
shown in Table 1, and Table 2 provides a summary of their characteristics. 
 
4.1 Cinnamon (Cinnamomumzeylanicum) 
Cinnamon(Lauraceae) has been used medicinally for thousands of years, and has been shown to 
have antidiabetic, antimicrobial, antispasmodic and lipid-lowering activities. Cinnamon contains 
a variety of bioactive compounds, including cinnamaldehyde, cinnamic acid, eugenol, and 
various essential oils. Several studies have indicated the anti-inflammatory and antioxidant 
activities of cinnamon, believed to be primarily due to its rich flavonoid content (Ozbayeret al., 
2014; Rao &Gan, 2014).Specifically, cinnamon appears to reduce the mRNA expression of 
certain inflammatory mediators, and inhibits the expression of COX-2 (Mashhadiet al., 2013).  
 
Study Characteristics:Jaafarpouret al. (2015a,b) conducted a double-blind study on the effects 
of cinnamon (1260mg a day, on days 1-3) on menstrual pain, as compared to ibuprofen and 
placebo. Cinnamon showed to significantly decrease the severity and duration of pain similarly 
to ibuprofen, but only after the first 8 hours. The cinnamon group also experienced significantly 
less nausea and vomiting than the placebo group. The study, as reported in two separate articles, 
had an unclear risk of bias in certain domains, due to insufficient detail regarding the 
 
 
methodology. Also, the small sample size is a limitation (n = 114).  The researchers did not 
report on adverse effects therefore no conclusions can be made with regards to its safety profile. 
While cinnamon bark is considered safe to use in the recommended dosages (3-6g daily of dried 
herb or 1.5-3.0ml (1:1 g/ml) fluid extract daily for < 6 weeks), it should be avoided in large 
quantities during pregnancy, in patients with gastrointestinal ulcers and if there is allergic 
hypersensitivity; no drug interactions have been reported (Brinker, 2010; Nabaviet al., 2015; 
Braun & Cohen, 2010). Cinnamon oil however, is contra-indicated in patients with liver 
conditions or when taking paracetamol (Nabaviet al., 2015). While prolonged use of 
Cinnamomum cassiais not recommended due to its high coumarin content (which has 
hepatotoxic and carcinogenic properties),Cinnamomumzeylanicum however has a low content of 
coumarins, and therefore may be more useful for long-term use (Medagama, 2015).  
 
4.2 Damask rose (Rosa damascena)  
Damask rose(Rosaceae), known for producing rose water and essential oil, is widely used in 
Traditional Medicine practices for treating abdominal pain, dysmenorrhoea, and inflammation. 
Some major compounds found in the molecular make up of this medicinal plant include: 
citrenellol, nerol, geranial and kaempferol (a flavonoid). Studies confirm its antioxidant, 
analgesic, and anti-inflammatory properties; the synergistic effects of its active compounds are 
believed to inhibit COX 1 and 2 (Boskabadyet al., 2011; Mahboubi, 2016).  
 
Study characteristics:The use of damask rose was examined in one RCT study included in this 
systematic review. The study concluded that doses of 600-800mg/per day taken from days 1-3 of 
the menstrual cycle, had similar effects to mefenamic acid for reducing the severity of primary 
dysmenorrhoea (Baniet al., 2014). The study had a low risk of bias in all of the domains 
assessed. While no adverse effects were reported in this study, damask rose may produce 
hypersensitivity and gastrointestinal effects, which are dose-dependant(Mahboubi, 2016). The 
recommended dosages for this medicinal herb are unknown.  
 
4.3 Dill (Anethumgraveolens)  
Dill (Apiaceae or Umbelliferae) is a medicinal plant traditionally used to treat gastrointestinal 
and rheumatic conditions. It is a known carminative and reduces abdominal spasms, bloating and 
indigestion. The major components in dill oil are tannins, terpenoids, cardiac glycosides and 
flavonoids, namely α-phellandrene, carvone, limonene, dill ether, anethum and sabinene. 
Sabinene in particular has been found to inhibit nitric oxide (NO) production, and is therefore 
 
 
believed to be responsible for dill’s anti-inflammatory activity (Jana &Shekhawat, 2010; 
Kazemi, 2015).  
 
Study characteristics:The use ofdill was examined by Heidarifaret al. (2014), who concluded 
that dill powder (2000mg/per day, beginning two days before menstruation until day three) was 
as effective as mefenamic acid for the alleviation of primary dysmenorrhoea. The results showed 
that a few participants in each group reported minor adverse effects, but the difference between 
the groups was insignificant (p = 0.621). Risk of bias was unclear regarding random sequence 
generation and selective outcome reporting; and the small sample size was another limitation.  
Side effects from the consumption of dill are rare; however it may cause hypersensitivity 
reactions in sensitive persons. The average recommended daily dose of dill seeds is 3g and 
essential oil is 0.1-0.3g (Ali, 2014). 
 
4.4 Felty germander (Teucriumpolium)  
Felty germander(Lamiaceae) is a rich source of neo-clerodanediterpenoids, such as α-pinene, 
ocimene, menthane and pulegone; it also contains flavonoids and aromatic compounds. A broad 
spectrum of pharmacological and therapeutic uses has been found through various studies, and 
these include: hepatoprotective, antioxidant, anti-inflammatory, antispasmodic, and 
antinociceptive effects. Its potent antispasmodic effects are believed to be due to its antagonistic 
action on acetylcholine, histamine and serotonin, and its anti-inflammatory effects due to its 
flavonoid and sterol constituents (Bahramikia&Yazdanparast, 2012; Hasani-Ranjbaret al., 2010; 
Parsaee&Shafiee-Nick, 2006).  
 
Study characteristics:In a triple-blind RCT by Abadianet al. (2016), the use of felty germander 
(1g/day)yielded similar results to mefenamic acid in relieving dysmenorrhoeal pain. Risk of bias 
in the study was low in the majority of the domains evaluated; however, one limitation of this 
study was the small sample size.No adverse effects were recorded by participants for the 
duration of the study. The safe and recommended dosages for this particular medicinal herb is 
unknown.Diterpenoids have been implicated in causing hepatotoxicity; therefore this medicinal 
plant should be used with caution in patients with hepatic abnormalities 
(Bahramikia&Yazdanparast, 2012; Hasani-Ranjbaret al., 2010; Parsaee&Shafiee-Nick, 2006). 
 
4.5 Fennel (Foeniculum vulgare) 
Fennel (Apiaceae or Umbelliferae family) has been used extensively in Traditional Medicine 
practices for many centuries for its antioxidant, carminative, anti-spasmodic, anti-inflammatory, 
 
 
and oestrogenic properties. This medicinal plant contains many active compounds, including 
fatty acids, phenolic and volatile components, while the essential oil’s main constituents are 
anethole (80%), estragole (10%) and fenchone (7.5%). Animal studies have shown fennel to 
have an effect on uterine contractility, and is believed reduce the intensity of contractions by 
inhibiting circulating oxytocin and prostaglandins (Badgujaret al., 2014; Gori et al., 2012; 
Rather et al., 2012).  
 
Study characteristics:Three RCTsassessing the effectiveness of fennel for the treatment of 
primary dysmenorrhoea, were included in the review. Moslemiet al. (2012) compared fennel 
extract to vitamin E and placeboand found significantly lower pain scores on the visual analogue 
scale(VAS) in the fennel group in the second cycle (p< 0.05). The study authors did not provide 
sufficient information regarding allocation concealment or reasons for the high attrition rate. 
Bokaieet al. (2013) compared the effect of oral fennel drops to mefenamic acid on pain intensity 
(VAS) and severity of bleeding, and found no significant differences between the two groups, 
however the fennel group used significantly fewer NSAIDs (p< 0.05); these results suggest that 
the efficacy of fennel dropsis comparable to mefenamic acid. Protocol compliance was difficult 
due to the offensive smell and taste of the fennel drops. The study has a high risk of bias due to 
the inability to ensure blinding of participants (drops versus capsules).Nasehiet al. (2013) 
conducted a cross-over study on the effectiveness of the combination of fennel and vitamin E (60 
mg fennel extract/150 IU vitamin E) with ibuprofen on pain intensity associated with primary 
dysmenorrhoea. Results revealed that pain intensity (VAS) in the fennel/ vitamin E group was 
lower than in the ibuprofen group, in the first two hours. This study has an unclear risk for 
attrition bias due to insufficient reporting. According to Badgujaret al. (2014), there is a long 
historical ethnomedicinal application of fennel, with no reports of any hazardous side-effects; 
this suggests that fennel could be regarded as safe. Concerns over the potential carcinogenicity of 
estragole has led the European Union to set limits on the recommended daily intake, however 
when used as a whole herb, its other components (such as nevadensin, epigallocatechine, and 
anethole), exert a protective effect against estragole (Gori et al., 2012). The recommended 
dosage is between 900-1800mg/day (infusion) or 3-6ml/day (1:2 g/ml liquid extract) (Bone & 
Mills, 2013). 
 
4.6 Fenugreek (Trigonellafoenum-graecum)  
This medicinal plant of the Fabaceae family contains medicinal alkaloids (trigonelline), steroidal 
saponins (diosgenin and yamogenin), flavonoids, oils, coumarins and mucilage (Bahmaniet al., 
2016). The carminative, anti-diabetic, antioxidant, anti-inflammatory, anti-microbial and 
 
 
cholesterol-lowering effects of fenugreek have been widely studied (Yadav &Baquer, 2014). 
While its exact mechanism of action in dysmenorrhea has not been established, research has 
shown fenugreek to produce analgesic and anti-inflammatory effects by inhibiting the synthesis 
of prostaglandins (Varjaset al., 2011).  
 
Study characteristics: In a RCT by Younesyet al. (2014), fenugreek use was shown to 
significantly reduce pain intensity and duration; participants in this group also experienced less 
associated systemic symptoms and required fewer painkillers. This study received an unclear risk 
of bias in 2 of the 7 domains due to insufficient detail provided in the article. In a prospective, 
open-labeledstudy by Inanmdaret al. (2012), the clinical efficacy of fenugreek (6g/day)was 
compared to mefanamic acid, and a combination of fenugreek and dry cupping therapy.All three 
groups had a statistically significant reduction in lower abdominal pain (p< 0.001), and the 
percentage of pain reduction was 66.89%, 66.49%, and 62.88% in groups 1, 2 and 3 respectively. 
Safety was assessed by means of laboratory tests (coagulation profile, full blood count, and liver 
and kidney function markers). All values stayed within normal range, hence it is inferred that 
fenugreek is safe to use in these dosages.Due to the nature of this study, there was a high risk of 
bias due to lack of participant and assessor blinding.Fenugreek appears to have little or no side 
effects and no considerable drug interactions have been reported. The recommended dosage is 5-
10g powder taken three times daily or a liquid extract of 2-6ml/day (1:2 g/ml) (Bahmaniet al., 
2016; Braun & Cohen, 2010).  
 
4.7 Ginger (Zingiber officinale)  
Ginger (Zingiberaceae) is a rhizome indigenous to Asia. It contains a variety of vitamins, 
minerals, and compounds such as gingerol, shogaols, zingerone, sesquiterpenes, capsaicin, and 
caffeic acid (Semwalet al., 2015; Braun & Cohen, 2010). Both in vitro and in vivo studies have 
shown the analgesic and anti-inflammatory effects of ginger. Gingerols and shogaols have 
specifically been shown to inhibit COX 1 and 2, as well as lipoxygenase, thereby reducing the 
synthesis of prostaglandins and leukotrienes (Hoseinzadehet al., 2015;Semwalet al., 2015).  
 
Study characteristics:In a placebo-controlled study by Jenabi (2013), ginger (1500mg/day) was 
found to significantly reduce pain severity in students with primary dysmenorrhoea, with the 
majority of subjects reporting an improvement in their symptoms. No adverse effects were 
reported in the ginger group. The study had an unclear risk of bias relating to 
blinding.Similarly,Rahnamaet al. (2012) also found ginger to significantly improve severity of 
menstrual pain, evaluated by means of two dosage protocols. Protocol 1 (ginger taken 2 days 
 
 
before menses until day 3) produced a shorter duration of pain than protocol 1 (taken only on 
days 1-3).Ginger appeared to be very well tolerated, with only 5.1% of participants’ 
experiencing heartburn, while 8.7% in the placebo group reported nausea. The study was judged 
to have an unclear risk for attrition and reporting bias. Kashefiet al. (2014) compared the effects 
of ginger (1500mg/day) and zinc sulphate for primary dysmenorrhoea, with both the ginger and 
zinc groups experiencing a statistically significant reduction in severity of painas compared to 
the placebo (p< 0.05). Minimal adverse effects were reported in all three groups, namely: 
diarrhoea, heartburn and headaches, with no significant difference found among the groups. This 
study had an unclear risk for selection and attrition biases.Doses of up to 4g/day of ginger have 
been found to be safe in healthy human subjects, andginger is overall regarded as safe (Braun & 
Cohen, 2010). Minor adverse effects typically include gastrointestinal symptoms (eructation, 
heartburn and indigestion), and occur in low frequency (European Medicines Agency, 2012). 
 
4.8 Lemon balm (Melissa officinalis)  
Lemon balm (Lamiaceae) has long been used in Traditional Medicine practices for several 
ailments including menstrual problems, and research has confirmed its antispasmodic, 
antioxidant, anxiolytic and sedative effects. The volatile compounds of lemon balm include 
triterpenoids, phenolic acids and flavonoids, including α-pinene, citral, citronellal, and 
rosmarinic acid. These constituents (particularly rosmarinic acid) possess powerful 
antinociceptive and anti-inflammatory properties, while its relaxant effects are due to citral; these 
effects make lemon balm a useful antispasmodic (Braun & Cohen, 2010; Mirajet al., 2016; 
Shakeriet al., 2016).  
 
Study characteristics: In asingle-blind trial by Dehcheshmeh&Parvin (2016), lemon balm (tea) 
use was shown to have a similar efficacy to mefanamic acid in reducing menstrual pain and 
duration. This study however had a high risk of bias; due to the nature of the intervention 
(teabags versus capsules), blinding could not be achieved. Other limitations of this study were 
the small sample size and high attrition rate.Conventional clinical safety data on the use of lemon 
balm is absent; however, long-standing medicinal use has been documented. It is suggested that 
patients with thyroid disease, glaucoma, or who are using sedative medications, use this 
medicinal herb with caution. The therapeutic dosage range of lemon balm in fluid extract is 6-
12ml/day (1:1g/ml) (Mirajet al., 2016; Braun & Cohen, 2010; Brinker, 2010; Shakeriet al., 
2016). 
 
4.9 Noni (Morindacitrifolia)  
 
 
Although long since recognized as an important medicinal plant, Noni (Rubiaceae) has recently 
gained popularity as a food supplement worldwide. Noni contains a multitude of 
phytoconstituents, including micronutrients, terpenoids, flavonoids, alkaloids, saponins, steroids 
and tannins. Noni has been shown to selectively inhibit COX-1 and COX-2 enzymes, thus has 
analgesic and anti-inflammatory effects, primarily due to the action of scopoletin, quercetin, and 
ursolic acid (Assiet al., 2015; Braun & Cohen, 2010; Ali et al., 2016; Motshakeri&Ghazali, 
2015).  
 
Study characteristics:The anti-inflammatory effect of noni (800mg/day) for primary 
dysmenorrhoea was examined in one RCT (Fletcher et al., 2013). The authors concluded that 
Noni did not produce a reduction in pain intensity or blood loss; the treatment group did 
however, have a lower erythrocyte sedimentation rate (ESR) level at the end of the study (p = 
<0.02), suggesting that noni may have an anti-inflammatory effect. Risk of bias was low in this 
study, with the exception of selective outcome reporting; limitations included the small sample 
size and high refusal rate at recruitment (71.4%). In large doses, noni may be hepatotoxic and 
induceshyperkalaemia; it is therefore not recommended in patients with liver or kidney 
dysfunction. The daily recommended dosage is 2g or 25ml juice twice daily (Ali et al., 2016; 
Assiet al., 2015; Braun & Cohen, 2010). 
 
4.10 Peppermint (Mentha piperita) 
Peppermint (Lamiaceae) is widely known for its antispasmodic, carminative, anti-inflammatory, 
and analgesic effects, particularly in the treatment of irritable bowel syndrome. Its major 
bioactive compounds menthol, menthone and isomenthone, and it also contains very low 
concentrations of estragole. Research suggests that peppermint inhibits prostaglandin 
concentration and oxytocin, as well as other pro-inflammatory mediators, namely leukotrienes 
and interleukins, while menthol stimulates ‘cold’ receptors – as a result of its antagonistic effect 
against calcium channels on neuronal membranes.This may explain its inhibitory effect on 
myometrium contractility of the uterus and analgesic effect in dysmenorrhoea (Cash et al., 2016; 
Kamatouet al., 2013; Mogosanet al., 2017).  
 
Study Characteristics:In a placebo-controlled trial byHeshmatiet al. (2016), peppermint use 
(990mg/day)produced a statistically significant difference in terms of pain severity, however not 
for duration of pain. There was an unclear risk of bias rating for allocation concealment and 
outcome data, as this information was insufficiently reported in the article. In the crossover study 
by Masoumiet al. (2016), the efficacy of peppermint compared favourably to mefenamic acid 
 
 
with regards to pain severity, need for analgesics, and associated symptoms (nausea and 
diarrhoea), however not for duration of pain. This study had a low risk of bias, except for the 
incomplete outcome data domain, as the reasons for withdrawals was not reported. Peppermint 
(and specifically the compound menthol) is considered safe for use in the appropriate dosages, 
however it is recommended that it be avoided in pregnancy, in patients with gallstones, hiatal 
hernia and significant gastroesophageal reflux disease (GERD). Adverse effects may include 
allergic reaction and gastrointestinal effects. The daily recommended dose is 6-9g/day (infusion), 
or fluid extract 1.5-4.5ml/day (1:2 g/ml) (Bone & Mills, 2013; Braun & Cohen, 2010; Brinker, 
2010; Kamatouet al., 2013). 
 
4.11 Rhubarb (Rheum emodi)  
Rhubarb(Polygonaceae), is a popular traditional Chinese medicine, especially known for its 
gastrointestinal (purgative, astringent) and musculoskeletal (anti-inflammatory) affinity, but has 
also been used to treat dysmenorrhoea and menorrhagia. The major phytoconstituents of rhubarb 
are: anthraquinones (including emodin), anthrones, stilbenes (including resveratrol), oxanthrone 
and flavonoids. Emodin in particular has been found to have an analgesic action (Gao et al., 
2011; Rehman et al., 2014; Takeokaet al., 2013).  
 
Study characteristics:In the RCT by Rehmanet al. (2015), rhubarb was shown to exhibit similar 
effects to mefanamic acid with regards to improving menstrual pain, duration, associated 
symptoms and quality of life, in students with primary dysmenorrhoea. The study received a 
high risk of bias however with regards to allocation concealment as the investigator assigned 
participants to the group and therefore knew what each participant would receive. Another 
limitation to this study was the small sample size. Rhubarb may cause mild gastrointestinal 
discomfort, and minor adverse effects were reported by 6 participants in this study. Only the 
baseline blood test results were reported in the article therefore it is unknown what effect rhubarb 
had on biochemic markers. Rhubarb is contraindicated in people who have epilepsy, gout, 
rheumatism, or those who have renal or gallbladder stones, due to its oxalic content (Rehman et 
al., 2014). The daily recommended dose is 10-30mg (0.5-1.5g of dried plant material) (WHO, 
1999). 
 
4.12 Thyme (Thymus vulgaris)   
Thyme (Lamiaceae) contains a combination of monoterpenes (namely thymol and carvacrol), as 
well as flavonoids and synthetic resin acids such as rosmarinic acid and caffeic acid. These 
constituents have been shown to exhibit antispasmodic and antioxidant activities; thyme is 
 
 
believed to be helpful in treating dysmenorrhoea due to its anticholinergic effects and ability to 
block serotoninergic pathways (Prasanth Reddy et al., 2016).  
 
Study characteristics:Salmalianet al. (2014) compared the effectiveness of thyme to 
ibuprofenin a placebo-controlled trial. Both the ibuprofen and thyme significantly reduced the 
severity of pain (p < 0.001) in a similar manner, and reduced the severity of associated 
symptoms (nausea and vomiting). The majority of participants in the thyme group rated 
satisfaction with treatment as great, the ibuprofen groupas moderate and the placebo group as 
ineffective.This study had an unclear risk of bias in all domains assessed, and therefore these 
results should be viewed with caution. The reported adverse events from thyme use are mild, 
however it is contraindicated in patients with gastritis, enterocolitis and congestive heart failure, 
as well as hypersensitive individuals (European Medicines Agency, 2013; Braun & Cohen, 2010; 
Brinker, 2010). The recommended daily doses are 3-12g/day (infusion) or a liquid extract of 2-
6ml/day (1:2 g/ml) and tincture 6-18ml/day (1:5 g/ml) (Bone & Mills, 2013; Braun & Cohen, 
2010). 
 
4.13 Valerian (Valeriana officinalis)  
Valerian(Valerianaceae) reportedly has several medicinal uses including sedative, anxiolytic and 
antidepressant effects, and has traditionally been used to treat insomnia, hypertension, angina, 
hepatic colic and menstrual cramps. Its main constituents include sesquiterpenoids (valerenic 
acid), epoxy iridoidesters (valepotriates, valtrate), amino acids (γ-aminobutyric acid, tyrosine) 
and alkaloids (Neamatiet al., 2014). Valepotriates (and valtrate) are responsible for valerian’s 
spasmolytic activity, by influencing the binding of calcium ions to smooth muscle 
(musculotrophic action) (Mirabiet al., 2011; Occhiutoet al., 2009).  
 
Study characteristics:In the placebo-controlled trial by Mirabiet al. (2011), valerian extract 
(675mg/day) was shown to significantly reduce pain and participants required significantly fewer 
sedative tablets than the placebo group (p< 0.001). The study had an unclear risk of bias with 
regards to allocation concealment and selective outcome reporting, due to insufficient 
information provided in the article.No participants reported adverse effects from the use of 
valerian, however one participant did withdraw from the valerian group due to dizziness, which 
may be a side effect. Adverse effects associated with valerian use are very rare and it has a 
favorable safety profile (Kelberet al., 2014). The recommended dosage is 3-9g/day (infusion) or 
2-6ml/day (fluid extract 1:2 g/ml) (Bone & Mills, 2013; Braun & Cohen, 2010). 
 
 
 
4.14 Wheat germ (Triticumaestivum) 
Wheat germ (Poaceae) is a by-product of the wheat milling industry, and a rich source of fibre 
and nutrients, particularly α-tocopherols (vitamin E), sterols, phytosterols and flavonoids. 
Beneficial properties attributed to wheat germ oil use are improved fertility, inhibition of platelet 
aggregation, reduced cholesterol, and its anti-ageing and anticancer effects. Vitamin E is a potent 
antioxidant and anti-inflammatory, and supplementation has been shown to alleviate the severity 
of pain in females with primary dysmenorrhoea (Brandolini& Hidalgo, 2012; Guvan& Kara, 
2015; Niuet al., 2013).  
 
Study characteristics:A placebo-controlled trial by Ataollahiet al. (2014) found wheat germ 
(1200mg/day)use to significantly reduce menstrual pain. Ten participants withdrew from the 
study, however it is unclear how many participants from each group were analysed, and the 
study had an unclear risk of bias in 4/7 domains.A few participants in both groups reported side 
effects but these were not specified or significantly different between the groups (p = 0.556). It is 
recommended that people who are gluten intolerant or who suffer from coeliac disease use wheat 
germ with caution. Furthermore, some mild adverse effects such as diarrhoea, flatulence, nausea 
and vertigo have been recorded; however more research is needed to confirm its safety 
(Brandolini& Hidalgo, 2012; Niuet al., 2013). 
 
4.15 Yarrow (Achilleamillefolium)  
Yarrow(Asteraceae) has many historical medicinal uses, with studies verifying its antispasmodic, 
anti-inflammatory, antihypertensive, and antiulcer effects, to name a few. Some highly bioactive 
antispasmodic compounds found in yarrow include: flavonoids, alkaloids (achilleine), cineol, 
borneol, α & β pinene, camphor, caryophyllene, thujene, rutin, monoterpenoids and 
sesquiterpenoids. The antispasmodic effects of yarrow are believed to be due to: anti-
prostaglandin effects, blockade of voltage dependent calcium channels, blockade of beta-
adrenergic receptors and inhibition of NOsynthesis (Moradiet al., 2013).  
 
Study characteristics:In a placebo-controlled study, the use of yarrow (tea) was shown to 
significantly reduce menstrual pain (Jenabi&Fereidoony, 2015). Risk of bias was low throughout 
all domains, except for selective outcome reporting. The medicinal use of yarrow can be 
considered safe; however hypersensitivity reactions are possible (European Medicines Agency, 
2011).  
 
Discussion 
 
 
This current systematic review included all relevant RCTs with reference to the treatment of 
primary dysmenorrhoea using medicinal plants of a single herb application, from English sources 
released from 2008 to 2016. RCTs are considered the most rigorous method of evaluating 
whether an intervention exhibits a cause-effect relationship between treatment and outcome, and 
provides level 1c evidence for effectiveness (according to the Joanna Briggs Institute levels of 
evidence) (The Joanna Briggs Institute, 2014). Systematic reviews are an important step in the 
development of evidence-based guidelines, which are beneficial to healthcare providers and their 
patients. In this review, most medicinal plants were shown to be beneficial in the treatment of 
primary dysmenorrhoea, with cinnamon (Cinnamomum zeylanicum), damask rose (Rosa 
damascena), dill (Anethumgraveolens),felty germander (Teucriumpolium), fennel (Foeniculum 
vulgare), fenugreek (Trigonellafoenum-graecum), lemon balm (Melissa officinalis), peppermint 
(Mentha piperita), rhubarb (Rheum emodi), and thyme (Thymus vulgaris) showing similar 
efficacy to commonly used NSAIDs (ibuprofen and mefanamic acid), while ginger (Zingiber 
officinale), valerian (Valeriana officinalis), wheat germ (Triticum aestivum) and yarrow 
(Achillea millefolium) showed efficacy in placebo-controlled trials.Research studies suggest that 
these medicinal plants have anti-inflammatory and analgesic properties, suggesting their possible 
mechanism of action in the treatment of this condition. Noni (Morinda citrifolia), despite its anti-
inflammatory effects however, was not shown to be effective in reducing pain associated with 
dysmenorrhoea.Based on these trials, it appears that these medicinal plants appear to be 
relatively safe with only minor adverse effects being reported for some. 
 
The results of this systematic review can be compared to similar previously conducted studies. 
The systematic review by Mirabiet al. (2014), which included 25 RCTs, aimed to determine the 
efficacy and safety of Iranian herbal medicines for primary dysmenorrhoea. The authors found 
evidence of efficacy for the use of fennel, ginger, and valerian in particular, however 
recommended further clinical trials necessary to evaluate therapeutic dosages and adverse 
effects. Chen et al. (2016) and Daily et al. (2015) conducted systematic reviews on the efficacy 
of ginger for the treatment of primary dysmenorrhoea using 6 and 7 RCTs respectively; both 
studies concluded that ginger may be effective for treating this condition however, future large-
scale trials were also recommended by the authors to fully evaluate its use and safety. 
Pattanittumet al. (2016) conducted a review on dietary supplements for the treatment of primary 
dysmenorrhoea, and included 27 RCTs (including 12 herbal medicines). The authors concluded 
that there is no high quality evidence to support the effectiveness of any dietary supplement for 
dysmenorrhoea, however more research is justified. 
 
 
 
Limitations of the current review is the paucity of eligible RCTs, lack of rigour with regards 
toreporting of results, small sample sizes, and short duration of the trials. Most of these studies 
made use of university students or women in a narrow age range as their population group, and 
therefore the results cannot be generalized to other age groups. For most medicinal plants there 
was only one included study, and not all studies reported on safety or adverse effects.Other 
limitations of this review include date limitations (2008-2016) of the inclusion criteria and only 
selecting trials published in English. 
 
Conclusion 
This systematic review provides information regarding the recent clinical evidence on the use of 
medicinal plants for the treatment of primary dysmenorrhoea. Level 1c evidence was found for 
all the medicinal plants evaluated, with the exception of noni (Morinda citrifolia).These findings 
need to be interpreted with caution, due to the risk of bias, small number of included RCTs and 
poor methodological quality of some of the trials. This current evidence, together with their 
long-standing historical use, adds to the knowledge-base on the use of these medicinal plants, 
and further large-scale studies are necessary to determine therapeutic dosages, long-term safety, 
adverse effects and interactions.  
 
Conflict of interest: None 
Acknowledgements: This work was financed and supported by the Universityof Johannesburg. 
The contents of this work are solely theresponsibility of the authors and do not represent the 
officialviews of UJ.  
 
 
References 
 
Abadian, K., Keshavarz, Z., Mojab, F., Majd, H.A., Abbasi, N.M. (2016). Comparison of the 
effect of mefenamic acid and Teucriumpolium on the severity and systemic symptoms of 
dysmenorrhea. Complementary Therapies in Clinical Practice; 22: 12-15. 
 
Ali, E.A. (2014). The pharmacological importance of Anethumgraveolens: a 
review.International Journal of Pharmacy & Pharmaceutical Sciences; 6(4): 11-13. 
 
Ali, M., Kenganora, M., Manjula, S.N. (2016). Health benefits of Morindacitrifolia (Noni): a 
review.Pharmacognosy Journal; 8(7): 321-331. 
 
Anuradha, D. (2015). Natural and Ayurvedic remedies for adolescence 
dysmenorrhea.International Journal of Phytotherapy; 5(1)33-36. 
 
Assi, R.A., Darwis, Y., Abdulbaqi, I.M., Khan, A.A., Vuanghao, L., Laghari, M.H. (2015). 
Morindacitrifolia (Noni): A comprehensive review on its industrial uses, pharmacological 
activities, and clinical trials. Arabian Journal of Chemistry; 1: 1-12.  
 
Ataollahi, M., Akbari, S., Mojab, F &Majd, H. (2014). The effect of wheat germ extract on the 
severity of primary dysmenorrhoea: Journal of Jahrom University of Medical Sciences; 12(1): 
59-63. 
 
Badgujar, S.B., Patel, V.V., Bandivdekar, A.H. (2014). Foeniculum vulgare mill: a review of its 
botany, phytochemistry, pharmacology, contemporary application and toxicology.Biomedical 
Research International; 2014:842674. doi: 10.1155/2014/842674. 
 
Bahmani, M., Shirzad, H.,Mirhosseini, M., Mesripour, A.,Rafieian-Kopaei, M. (2016). A review 
on ethnobotanical and therapeutic uses of Fenugreek (Trigonellafoenum-graecum). Journal of 
Evidence-Based Complementary & Alternative Medicine; 21(1): 53-62. 
 
Bahramikia, S., Yazdanparast, R. (2012). Phytochemistry and medicinal properties of 
TeucriumpoliumL. (Lamiaceae). Phytotherapy Research; 26: 1581-1593.  
 
 
 
Bani, S., Hasanpour, S., Mousavi, Z., Garehbaghi, P. M., Gojazadeh, M. (2014). The effect of 
Rosa Damascena extract on primary dysmenorrhoea: a double-blind cross-over clinical trial: 
Iranian Red Crescent Medical Journal; 16(1): 1-6.  
 
Berger, V.W., Alperson, S.Y. (2010). A general framework for the evaluation of clinical trial 
quality. Reviews on Recent Clinical Trials; 4:2: 79-88. 
 
Bokaie, M., Farajkhoda, T., Enjezab, B., Khoshbin, A., Mojgan, K.Z. (2013). Oral fennel 
(Foeniculum vulgare) drop effect on primary dysmenorrhoea: Effectiveness of herbal drug. 
Iranian Journal of Nursing & Midwifery Research; 18(2): 128-132. 
 
Bone, K., Mills, S. (2013). Principles and practice of phytotherapy. 2nd Edition, Churchill 
Livingstone, Elsevier: Australia.  
 
Boskabady, M.H., Eftekhar, N., Kaveh, M. (2013). Possible mechanism(s) of the relaxant effects 
of Achilleawilhelmsii on guinea-pig tracheal chains. Iranian Journal of Pharmacological 
Research; 12(2): 381-387.  
 
Brandolini, A., Hidalgo, A. (2012). Wheat germ: not only a by-product. International Journal of 
Food Sciences & Nutrition; 63: 71-74. 
 
Braun, L., Cohen, M. (2010). Herbs and Natural Supplements: An Evidence-Based Guide.3rd 
Edition, Churchill Livingstone, Elsevier: Australia.  
 
Brinker, F. (2010). Herbal contraindications and drug interactions plus herbal adjuncts with 
medicines. 4th Edition, Eclectic Medical Publication: Oregon. 
 
Cash, B.D., Epstein, M.S., Shah, S.M. (2016). A novel delivery system of peppermint oil is an 
effective therapy for irritable bowel syndrome symptoms. Digestive Diseases & Sciences; 61(2): 
560-71.  
 
Chen, C.X., Barrett, B., Kwekkeboom, K.L. (2016). Efficacy of oral ginger (Zingiberofficinale) 
for dysmenorrhoea: a systematic review and meta-analysis. Journal ofEvidence-Based 
Complementary & Alternative Medicine; (1): 1-10.  
 
 
 
Cochrane Collaboration. (2016). Criteria for judging risk of bias in the ‘Risk of bias’ assessment 
tool. Available from: 
http://handbook.cochrane.org/chapter_8/table_8_5_d_criteria_for_judging_risk_of_bias_in_the_
risk_of.htm. (Last accessed 30/05/2017).  
 
Cooper, K.L., Harris, P.E., Relton, C., Thomas, K.J. (2013). Prevalence of visits to five types of 
complementary and alternative medicine practitioners by the general population: asystematic 
review.Complementary Therapies in Clinical Practice; 19: 214-220. 
 
Daily, J.W., Zhang, X., Kim, D.S., Park, S. (2015). Efficacy of ginger for alleviating the 
symptoms of primary dysmenorrhoea: a systematic review and meta-analysis of randomized 
clinical trials. Pain Medicine; 16: 2243–2255. 
 
Dehcheshmeh, F.S., Parvin, N. (2016). The effect of mefenamic acid and Melissa officinalis on 
primary dysmenorrhoea: a randomized clinical trial study. International Journal of 
Pharmacognosy& Phytochemical Research; 8(8): 1286-1292. 
 
Dragoman, M.V. (2014). The combined oral contraceptive pill - recent developments, risks and 
benefits.Best Practice & Research Clinical Obstetrics and Gynaecology; 28: 825-834. 
 
Dwivedi, A.K., Gurjar, V., Kumar, S., Singh, N. (2015). Molecular basis for nonspecificity of 
nonsteroidal anti-inflammatory drugs (NSAIDs). Drug Discovery Today; 1(1): 1-11. 
 
Edwards, K. (2008). Obstetrics and gynecology: Dewhurst’s textbook of obstetrics and 
gynaecology. 1st Edition. Wiley-Blackwell: USA. Pp. 404-406. 
 
Ekor, M. (2013). The growing use of herbal medicines: issues relating to adverse reactions and 
challenges in monitoring safety.Frontiers in Pharmacology; 4: 177. 
 
European Medicines Agency. (2011). Committee on Herbal Medicinal Products (HMPC). 
Assessment report on Achilleamillefolium L., herba. United Kingdom. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-
_HMPC_assessment_report/2011/09/WC500115468.pdf. 
 
 
 
European Medicines Agency. (2012). Committee on Herbal Medicinal Products (HMPC). 
Assessment report on Zingiberofficinale Roscoe, rhizome. United Kingdom. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-
_HMPC_assessment_report/2012/06/WC500128140.pdf. Accessed 05/06/2017. 
 
European Medicines Agency. (2013). Committee on Herbal Medicinal Products (HMPC). 
Assessment report on Thymus vulgaris L., vulgaris zygis L., herba. United Kingdom. Available 
fromhttp://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-
_HMPC_assessment_report/2014/06/WC500167810.pdf 
 
Fletcher, H.M., Dawkins, J., Rattray, C., Wharfe, G., Reid, M., Gordon-Strachan, G. (2013). 
Morindacitrifolia (Noni) as an anti-inflammatory treatment in women with primary 
dysmenorrhoea: A randomised double-blind placebo-controlled trial. Obstetrics & Gynecology 
International; 1: 1-6. 
 
Gao, Y., Liu, H., Deng, L., Zhu, G., Xu, C., Li, G., Liu, S., Xie, J., Liu, J., Kong, F., Wu, R., Li, 
G., Liang, S.Effect of emodin on neuropathic pain transmission mediated by P2X2/3 receptor of 
primary sensory neurons.Brain Research Bulletin; 84(6): 406-13. 
 
Gori, L., Gallo, E.,Mascherini, V.,Mugelli, A.,Vannacci, A., Firenzuoli, F. (2012). Can estragole 
in fennel seed decoctions really be considered a danger for human health? A fennel safety 
update. Evidence Based Complementary & Alternative Medicine; 860542. 
 
Guvan, M., Kara, H.H. (2015). Some chemical and physical properties, fatty acid composition 
and bioactive compounds of wheat germ oils extracted from different wheat cultivars. Journal of 
Agricultural Sciences; 22:433-443. 
 
Hasani-Ranjbar, S., Nayebi, N., Larijani, B., Abdollahi, M. (2010). A systematic review of the 
efficacy and safety of Teucrium species; from anti-oxidant to anti-diabetic effects. International 
Journal of Pharmacology; 6: 315-325. 
 
Heidarifar, R., Mehran, N., Heidari, A., Tehran, H.A., Koohbor, M., Mansourabad, M.K. (2014). 
Effect of Dill (Anethumgraveolens) on the severity of primary dysmenorrhoea compared with 
mefenamic acid: a randomized, double-blind trial. Journal of Research in Medicinal Sciences; 
19: 326-30.  
 
 
 
Heshmati, A., Dolatian, M., Mojab, F., Shakeri, N., Nikkhah, S., Mahmoodi, Z. (2016). The 
effect of peppermint (Menthapiperita) capsules on the severity of primary dysmenorrhea. 
Journal of Herbal Medicine; 138: 1-5. 
 
Higgins, J.P.T., Green, S. (2008). Cochrane handbook for systematic reviews of interventions. 
John Wiley & Sons, Ltd: West Sussex. 
 
Hoseinzadeh, K., Daryanoosh, F., Baghdasar, P.J., Alizadeh, H. (2015). Acute effects of ginger 
extract on biochemical and functional symptoms of delayed onset muscle soreness.Medical 
Journal of the Islamic Republic of Iran; 29:261. 
 
Inanmdar, W., Sultana, A., Mubeen, U., Rahman, K. (2012). Clinical efficacy of 
Trigonellafoenum-graecum(Fenugreek) and dry cupping therapy on intensity of pain in patients 
with primary dysmenorrhoea: Chinese Journal of Integrative Medicine; 1: 1-8. 
 
Jaafarpour, M., Hatefi, M., Khani, A., Khajavikhan, J. (2015a). Comparative effect of cinnamon 
and ibuprofen for treatment of primary dysmenorrhoea: a randomized double-blind clinical trial. 
Journal of Clinical & Diagnostic Research; 9(4): 4-7.  
 
Jaafarpour, M., Hatefi, M., Najafi, F., Khajavikhan, J., Khani, A. (2015b). The effect of 
cinnamon on menstrual bleeding and systemic symptoms with primary dysmenorrhea. Iranian 
Red Crescent Medical Journal; 17(4): 27-32.  
 
Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J.M., Gavaghan, D.J., 
McQuay, H.J. (1996). Assessing the quality of reports of randomized clinical trials: is blinding 
necessary?Controlled Clinical Trials; 17(1): 1-12. 
 
Jana, S.,Shekhawat, G.S. (2010). Anethumgraveolens: an Indian traditional medicinal herb and 
spice.Pharmacognosy Reviews; 4(8): 179-184.  
 
Jenabi, E. (2013). The effect of ginger for relieving of primary dysmenorrhoea: The Journal of 
the Pakistan Medical Association; 63 (1): 8-10.   
 
 
 
Jenabi, E., Fereidoony, B. (2015). Effect of Achilleamillefolium on relief of primary 
dysmenorrhoea: a double-blind randomized clinical trial: Journal of Pediatric Adolescent 
Gynaecology; 28: 402-404.  
 
Jørgensen, L., Paludan-Müller, A.S., Laursen, D.R.T., Savović, J., Boutron, I., Sterne, J.A.C., 
Higgins, J.P.T., Hróbjartsson, A. (2016). Evaluation of the Cochrane tool for assessing risk of 
bias in randomized clinical trials: overview of published comments and analysis of user practice 
in Cochrane and non-Cochrane reviews. Systematic Reviews; 5: 80. 
 
Ju, H., Jones, M., Mishra, G.D. (2014a). Premenstrual syndrome and dysmenorrhea: symptom 
trajections over 13 years in young adults.Maturitas; 48: 33-105. 
 
Ju, H., Jones, M., Mishra, G.D. (2014b). The prevalence and risk factors of dysmenorrhea. 
Epidemiologic Reviews; 104-113. 
 
Kamatou, G.P., Vermaak, I., Viljoen, A.M., Lawrence, B.M. (2013). Menthol: a simple 
monoterpene with remarkable biological properties. Phytochemistry; 96: 15-25. 
 
Kannan, P., Chapple, C.M., Miller, D., Claydon, L.S., Baxter, G.D. (2015). Menstrual pain and 
quality of life in women with primary dysmenorrhea: Rationale, design, and interventions of a 
randomized controlled trial of effects of a treadmill-based exercise intervention.Contemporary 
Clinical Trials; 42: 81-89. 
 
Kashefi, F., Khajehei, M., Tabatabaeichehr, M., Alavinia, M., Asili, J. (2014). Comparison of the 
effect of ginger and zinc sulfate on primary dysmenorrhoea: a placebo-controlled randomized 
trial.  Pain Management Nursing; 15(4): 826-833. 
 
Kazemi, M. (2015). Phenolic profile, antioxidant capacity and anti-inflammatory activity of 
Anethumgraveolens L. essential oil.Natural Products Research; 29(6): 551-553. 
 
Kelber, O., Nieber, K., Kraft, K. (2014).  Valerian: no evidence for clinically relevant 
interactions.Evidence Based Complementary & Alternative Medicine; 2014: 879396. 
 
Kolhe, S., Deb, S. (2011). Dysmenorrhoea. Obstetrics, Gynaecology& Reproductive Medicine; 
21(11): 311-316.  
 
 
 
Kural, M., Noor, N.N., Pandit, D., Joshi, T., Patil, A. (2015). Menstrual characteristics and 
prevalence of dysmenorrhea in college going girls. Journal of Family Medicine & Primary Care; 
4(3): 426–431. 
 
Latthe, P.M., Champaneria, R., Khan, K.S. (2011). Dysmenorrhoea. Clinical Evidence; 2: 813.  
 
Mahboubi, M. (2016). Rosa damascena as holy ancient herb with novel applications.Journal of 
Traditional and Complementary Medicine; 6(1): 10-16. 
 
Marjoribanks, J., Ayeleke, R., Farquhar, C., Proctor, M. (2015). Nonsteroidal anti-inflammatory 
drugs for dysmenorrhoea. Gynaecology& Fertility Group. Cochrane. Available from: 
http://www.cochrane.org/CD001751/MENSTR_nonsteroidal-anti-inflammatory-drugs-
dysmenorrhoea. Accessed 21/07/2017. 
 
Mashhadi, N.S., Ghiasvand, R., Askari, G., Feizi, A., Hariri, M., Darvishi, L., Barani, A., 
Taghiyar, M., Shiranian, A., Hajishafiee, M. (2013). Influence of ginger and cinnamon intake on 
inflammation and muscle soreness endued by exercise in Iranian female athletes. International 
Journal of Preventative Medicine; 4 (Suppl 1): S11–S15. 
 
Masoumi, S.Z., Asl, H.R., Poorolajal, J., Panah, M.H., Oliaei, S.R. (2016). Evaluation of mint 
efficacy regarding dysmenorrhoea in comparison with mefenamic acid: a double-blinded 
randomized crossover study. Iranian Journal of Nursing & Midwifery Research; 21(4):363-367.  
 
Medagama, A.B. (2015). The glycaemic outcomes of Cinnamon, a review of the experimental 
evidence and clinical trials. Nutrition Journal; 14: 108. 
 
Mirabi, P., Dolatian, M., Mojab, F., Majd, H.A. (2011). Effects of valerian on the severity and 
systemic manifestations of dysmenorrhea. International Journal of Gynecology and Obstetrics; 
115: 285-288.  
 
Mirabi, P., Alamolhoda, S.H., Esmaeilzadeh, S., Mojab, F. (2014). Effect of medicinal herbs on 
primary dysmenorrhoea – a systematic review.Iranian Journal of Pharmaceutical Research; 
13(3): 757-767. 
 
 
 
Miraj, S., Rafieian-Kopaei, M.,Kiani, S. (2016). Melissa officinalis L: a review study with an 
antioxidant prospective. Journal of Evidence-Based Complementary & Alternative Medicine; 1: 
1-10. 
 
Mogosan, C., Vostinaru, O., Oprean, R., Heghes, C., Filip, L., Balica, G., Moldovan, R.I. (2017). 
A comparative analysis of the chemical composition, anti-inflammatory, and antinociceptive 
effects of the essential oils from three species of Mentha cultivated in Romania. Molecules; 
22(2): 263. 
 
Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group. (2009). Preferred reporting 
items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med; 
6(7):e1000097.  
 
Moradi, M., Rafieian-Koupaei, M., Imani-Rastabi, R., Nasiri, J., Shahrani, M., Rabiei, Z., 
Alibabaei, Z. (2013). Antispasmodic Effects of Yarrow (AchilleaMillefolium L.) Extract in the 
Isolated Ileum of Rat. African Journal of Traditional, Complementary & Alternative Medicine; 
10(6): 499–503. 
 
Moslemi, L., Aghamohammadi, A., Bekhradi, R., Zafari, M. (2012). The comparison effect of 
vitamin E and Fennel extract on intensity of primary dysmenorrhea. Journal of Mazandaran 
University of Medical Sciences;22(88):103–7. 
 
Motshakeri, M., Ghazali, H.M. (2015). Nutritional, phytochemical and commercial quality of 
Noni fruit: a multi-beneficial gift from nature. Trends in Food Science & Technology; 45: 118-
129. 
 
Nabavi, S.F., Di Lorenzo, A., Izadi, M., Sobarzo-Sanchez, E., Daglia, M., Nabavi, S.M. (2015). 
Antibacterial effects of cinnamon: from farm to food, cosmetic and pharmaceutical industries: 
Nutrients; 7: 7729-7748. 
 
Nasehi, M., Sehhatie, F., Zamanzadeh, V., Delezar, A., Javadzadeh, Y., Chongheralu, B.M. 
(2013). Comparison of the effectiveness of combination of fennel extract/vitamin E with 
ibuprofen on the pain intensity in students with primary dysmenorrhea. Iranian Journal of 
Nursing & Midwifery Research; 18(5): 355-359.  
 
 
 
Neamati, A., Chaman, F., Hosseini, M., Boskabady, M.H. (2014). The effects of Valeriana 
officinalis L. hydro-alcoholic extract on depression like behavior in ovalbumin sensitized 
rats.Journal of Pharmacy &Bioallied Sciences; 6(2): 97–103. 
 
Niu, L., Jiang, S., Pan, L., Pang, M. (2013). Characterisation of wheat germ oil in terms of 
volatile compounds, lipid composition, thermal behaviour, and structure. International Journal 
of Food Properties; 16: 1740-1749. 
 
Occhiuto, F., Pino, A., Palumbo, D. R., Samperi, S., De Pasquale, R., Sturlese, E.,Circosta, C. 
(2009). Relaxing effects of Valeriana officinalis extracts on isolated human non-pregnant uterine 
muscle. Journal of Pharmacy & Pharmacology; 61:251-256. 
 
Olivo, S.A., Macedo, L.C., Gadotti, I.C., Fuentes, J., Stanton, T., Magee, D. (2008). Scales to 
assess the quality of randomized controlled trials: a systematic review. Physical Therapy; 8:22: 
156-175. 
 
Omidvar, S.,Esmailzadeh, S., Baradaran, M.,Basirat, Z. (2012). Effect of fennel on pain intensity 
in dysmenorrhoea: a placebo-controlled trial.An International Quarterly Journal of Research in 
Ayurveda; 33(2): 311-313. 
 
Ortiz, M.I. (2010). Primary dysmenorrhea among Mexican university students: prevalence, 
impact and treatment.European Journal of Obstetrics & Gynecology Biology; 152: 73-77. 
 
Ozbayer, C., Kurt, H., Ozdemir, Z., Tuncel, T., Saadat, S.M., Burukoglu, D., Senturk, H., 
Degirmenci, I., Gunes, H.V. (2014). Gastroprotective, cytoprotective and antioxidant effects of 
Oleum cinnamomi on ethanol induced damage. Cytotechnology; 66(3): 431–441. 
 
Ozerdogen, N., Sayiner, D., Ayranci, U., Unsal, A., Giray, S. (2009). Prevalence and predictors 
of dysmenorrhoea among students at a university in Turkey. International Journal of 
Gynecology & Obstetrics; 107:39-43.  
 
Parsaee, H., Shafiee-Nick, R. (2006). Antispasmodic and antinociceptive effects of 
Teucriumpolium aqueous extract. Iranian Biomedical Journal; 10: 145-149. 
 
 
 
Parveen, N., Majeed, R., Rajar, U.D.M. (2009). Familial predisposition of dysmenorrhoea 
among medical students. Pakistan Journal of Medical Sciences; 25(5): 857-860.  
 
Pattanittum, P., Kunyanone, N., Brown, J., Sangkomkamhang, U. S., Barnes, J., Seyfoddin, V., 
Marjoribanks, J. (2016). Dietary supplements for dysmenorrhoea. Cochrane Database of 
Systematic Reviews; 3: CD002124. 
 
Porter, R.S. (2011). The Merck Manual; 19th Edition, New Jersey: Merck Sharp and Dohme 
Corp. p. 2513. 
 
Potur, D.C.K.,Komurcu, N. (2014). The effects of local low-dose heat application on 
dysmenorrhea.North American Society for Pediatric and Adolescent Gynecology; 27: 216-221. 
 
Potur, D.C.K., Bilgin, N.C.,Komurcu, N. (2014). Prevalence of dysmenorrhea in university 
students in Turkey: effect on daily activities and evaluation of different pain management 
methods. Pain Management Nursing; 15(4): 768-777. 
 
Prasanth Reddy, V., Ravi Vital, K., Varsha, P.V., Satyam, S. (2014). Review on Thymus vulgaris 
Traditional Uses and Pharmacological Properties. Medicinal & Aromatic Plants; 3:164. 
 
Rahnama, R., Montazeri, A., Huseini, H.F., Kianbakht, S., Naseri, M. (2012). Effect of 
Zingiberofficinale R. rhizomes (ginger) on pain relief in primary dysmenorrhea: a placebo 
randomized trial. BMC Complementary & Alternative Medicine; 12(92): 1-8. 
 
Rao, P.V., Gan, S.H. (2014). Cinnamon: amultifaceted medicinal plant. Evidence Based 
Complementary & Alternative Medicine; 642942. 
 
Rather, M.A., Dar, B.A., Sofi, S.N., Bhat, B.A.,Qurishi, M. A. (2012). Foeniculum vulgare: a 
comprehensive review of its traditional use, phytochemistry, pharmacology, and safety.Arabian 
Journal of Chemistry; 1:1-9. 
 
Rehman, H., Begum, W., Anjum, F., Tabasum, H. (2014). Rheum emodi (Rhubarb): a fascinating 
herb. Journal of Pharmacognosy&Phytochemistry; 3(2): 89-94.  
 
 
 
Rehman, H., Begum, W., Anjum, F., Tabasum, H., Zahid, S. (2015). Effect of rhubarb (Rheum 
emodi) in primary dysmenorrhoea: single-blind randomized controlled trial. Journal of 
Complementary Integrative Medicine; 12(1): 61-69.  
 
Salmalian, H., Saghebi, R., Moghadamnia, A.A., Bijani, A., Faramarzi, M., Amiri, F.N., 
Bakouei, F., Behmanesh, F., Bekhradi, R. (2014). Comparative effect of Thymus vulgaris and 
ibuprofen on primary dysmenorrhoea: a triple-blind clinical study. Caspian Journal of Internal 
Medicine; 5(2):82-88. 
 
Semwal, R.B., Semwal, D.K., Combrinck, S., Viljoen, A.M. (2015). Gingerols and shogaols: 
important nutraceutical principles for ginger.Phytochemistry; 117: 554-568. 
 
Shakeri, A., Sahebkar, A.,Javadi, B. (2016). Melissa officinalis L. – a review of its 
phytochemistry and pharmacology. Journal of Ethnopharmacology; 188: 204-228. 
 
Singh, N., Rai, S. (2017). Primary dysmenorrhoea. IndianObstetrics &Gynaecology; 7(2): 38-45. 
 
Smith, R.,Kaunitz, A. (2014). Treatment of primary dysmenorrhea in adult women. Available 
from: http://www.uptodate.com/contents/treatment-of-primary-dysmenorrhea-in-adult-women. 
(Last accessed 23 July 2017).  
 
Takeoka, G.R., Dao, L., Harden, L., Pantoja, A., Kuhl, J. C. (2013). Antioxidant activity, 
phenolic and anthocyanin contents of various rhubarb (Rheum spp.) varieties. International 
Journal of Food Science & Technology; 48: 172-178. 
 
The Joanna Briggs Institute (JBI). (2014). New JBI levels of evidence. Available from: 
http://joannabriggs.org/assets/docs/approach/JBI-Levels-of-evidence_2014.pdf. (Last accessed 1 
February 2017).  
 
Varjas, T., Nowrasteh, G., Budán, F., Horváth, G., Cseh, J., Gyöngyi, Z., Makai, S., Ember, I. 
(2011). The effect of fenugreek on the gene expression of arachidonic acid metabolizing 
enzymes. Phytotherapy Research; 25(2): 221-227. 
 
 
 
WHO (World Health Organization). (1999). Monographs on selected medicinal plants: Volume 
1. Available from: http://apps.who.int/medicinedocs/en/d/Js2200e/25.html. (Last accessed 20 
July 2017). 
 
WHO (World Health Organization). (2016). Draft: WHO guidelines on good herbal processing 
practices (GHPP) for herbal medicines. Available from: 
http://www.who.int/medicines/areas/quality_safety/quality_assurance/C-F-V-global_review-
draftWHO-GHPP2016.pdf?ua=1. Accessed 27 July 2017. 
 
Yadav, U.C., Baquer, N.Z. (2014). Pharmacological effects of Trigonellafoenum-graecumL. in 
health and disease. Pharmaceutical Biology; 52(2): 243-254. 
 
Younesy, S., Amiraliakbari, S., Esmaeili, S., Alavimajd, H., Nouraei, S. (2014). Effects of 
fenugreek seed on the severity and systematic symptoms of dysmenorrhea. Journal of 
Reproduction & Infertility; 15(1): 41-48. 
 
 
